Insiders: Iran-U.N. Atomic Talks Yielded Little Traction

Global Security Newswire Staff
See more stories about...
Global Security Newswire Staff
Oct. 2, 2013, 9:02 a.m.

Ir­an and the In­ter­na­tion­al Atom­ic En­ergy Agency ap­peared to gain little trac­tion last week in clear­ing the way for a stalled nuc­le­ar probe, des­pite pos­it­ive state­ments by par­ti­cipants, en­voys told Re­u­ters on Wed­nes­day.

Last Fri­day’s meet­ing was the 11th between Ir­an and the IAEA since early last year to con­sider po­ten­tial ground rules for the U.N. nuc­le­ar watch­dog to look in­to in­tel­li­gence find­ings that the Middle East­ern na­tion once may have en­gaged sci­entif­ic activ­it­ies rel­ev­ant to atom­ic-arms de­vel­op­ment. The al­leged work could in­clude nuc­le­ar-rel­ev­ant ex­plos­ives tests, as well as work on a nuc­le­ar-bomb trig­ger at its Parchin mil­it­ary base.

Ir­a­ni­an del­eg­ates to last week’s Ir­an-IAEA talks — the first held un­der Ir­a­ni­an Pres­id­ent Has­san Rouh­ani — said Tehran hopes to break sig­ni­fic­ant ground on the mat­ter in a mat­ter of months, ac­cord­ing to an in­formed dip­lo­mat. However, pre­vi­ous hints at for­ward move­ment ul­ti­mately led nowhere, mul­tiple en­voys said.

Ir­an and the U.N. or­gan­iz­a­tion are next slated to meet on Oct. 28, fol­low­ing two days of sep­ar­ate atom­ic dis­cus­sions between Tehran and six ma­jor gov­ern­ments. The five per­man­ent U.N. Se­cur­ity Coun­cil mem­ber na­tions and Ger­many for years have sought more con­crete as­sur­ances that Ir­an’s nuc­le­ar pro­gram is not sup­port­ing de­vel­op­ment of a weapon cap­ab­il­ity.

A Sen­ate pan­el is not ex­pec­ted to con­sider a House-passed Ir­an sanc­tions bill for sev­er­al more weeks, at least, pos­sibly pla­cing any de­bate on the le­gis­la­tion after Ir­an’s sched­uled meet­ing with the “P-5+1” na­tions, Re­u­ters re­por­ted sep­ar­ately on Tues­day.

Mean­while, Ir­an’s law­makers broadly backed Rouh­ani’s nuc­le­ar-re­lated out­reach at the U.N. Gen­er­al As­sembly last week, Re­u­ters re­por­ted on Wed­nes­day, cit­ing state me­dia.

What We're Following See More »
SEVEN-POINT LEAD IN A FOUR-WAY
Quinnipiac Has Clinton Over 50%
55 minutes ago
THE LATEST

Hillary Clinton leads Donald Trump 51%-41% in a new Quinnipiac poll released today. Her lead shrinks to seven points when the third-party candidates are included. In that scenario, she leads 45%-38%, with Gary Johnson pulling 10% and Jill Stein at 4%.

Source:
PROCEDURES NOT FOLLOWED
Trump Not on Ballot in Minnesota
2 hours ago
THE LATEST
MIGHT STILL ACCEPT FOREIGN AND CORPORATE MONEY
Chelsea to Stay on Board of Clinton Foundation
3 hours ago
THE LATEST

Is the Clinton family backtracking on some of its promises to insulate the White House from the Clinton Foundation? Opposition researchers will certainly try to portray it that way. A foundation spokesman said yesterday that Chelsea Clinton will stay on its board, and that the "foundation’s largest project, the Clinton Health Access Initiative, might continue to accept foreign government and corporate funding."

Source:
INTERCEPT IN MIDDLE EAST
Navy Calls Iranian Ships’ Actions Dangerous, Unprofessional
4 hours ago
THE LATEST

"Four Iranian ships made reckless maneuvers close to a U.S. warship this week, the Pentagon said Thursday, in an incident that officials said could have led to dangerous escalation." The four Iranian vessels engaged in a "high-speed intercept" of a U.S. destroyer in the Strait of Hormuz. A Navy spokesman said the Iranina actions "created a dangerous, harassing situation that could have led to further escalation including additional defensive measures" by the destroyer.

Source:
$300 SAVINGS CARD
Under Pressure, EpiPen Maker Drops Prices
4 hours ago
THE LATEST

Amid public outcry and the threat of investigation by the Senate Judiciary Committee, Mylan has agreed to effectively drop the price of EpiPens. "The company, which did not lower the drug's list price, said it would reduce the patient cost of EpiPen through the use of a savings card, which will cover up to $300 of EpiPen 2-Pak."

Source:
×